Tandem Diabetes Care, Inc. TNDM

SAN DIEGO, October 01, 2026--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial markets close on Thursday, November 5, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2026 financial and operating results.

Tandem Diabetes Care has recently launched its Tandem Mobi automated insulin delivery system in 12 countries across Europe and Israel, using Dexcom G7 continuous glucose monitoring and Control-IQ+ technology to automatically adjust insulin every 5 minutes. The international rollout of this small, iPhone-controlled pump with flexible wear options and a 200-unit cartridge broadens Tandem’s technology ecosystem for people living with diabetes outside the United States. We’ll now explore how...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Tandem Diabetes (NASDAQ:TNDM) and the best and worst performers in the healthcare technology industry.

MILAN, September 28, 2026--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.

A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.

Tandem Diabetes Care (TNDM) is back in focus after recent share price swings, with the stock closing at US$16.87. Investors are weighing mixed return figures and fresh financial data on revenue and profit. The share price of US$16.87 comes after a sharp 24.42% decline in the 1 month share price return. However, the 3 month share price return is up 17.64%, and the 1 year total shareholder return of 34.21% indicates momentum that has been building over a longer period, despite weaker 3 and 5...

Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.

The diabetes tech firm is preparing for the launch of new devices, including a tubeless insulin pump and a fully closed loop automated insulin delivery system.

Over the last six months, Tandem Diabetes’s shares have sunk to $22.45, producing a disappointing 13.7% loss - a stark contrast to the S&P 500’s 10.5% gain. This might have investors contemplating their next move.

Tandem Diabetes met Wall Street’s revenue and profit expectations in Q2, but the market responded negatively, likely reflecting investor caution around the pace of U.S. pump shipments and the near-term impact of the company’s business model transition. Management highlighted stronger pump shipment growth internationally and early traction from its new pharmacy channel in the U.S. CEO John Sheridan emphasized that the company’s ability to drive operational efficiencies and expand access to its te

Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) jumped 18.2% in the afternoon session after the company reported second-quarter results that showed improved profitability and a narrower-than-expected loss per share.